HK1093494A1 - (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists - Google Patents

(thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Info

Publication number
HK1093494A1
HK1093494A1 HK07100087.7A HK07100087A HK1093494A1 HK 1093494 A1 HK1093494 A1 HK 1093494A1 HK 07100087 A HK07100087 A HK 07100087A HK 1093494 A1 HK1093494 A1 HK 1093494A1
Authority
HK
Hong Kong
Prior art keywords
carbamoyl
thio
receptor antagonists
cyclohexane derivatives
cyclohexane
Prior art date
Application number
HK07100087.7A
Other languages
English (en)
Inventor
Eva Againe Csongor
Janos Galambos
Katalin Nogradi
Istvan Vago
Istvan Gyertyan
Bela Kiss
Istvan Laszlovszky
Judit Laszy
Katalin Saghy
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of HK1093494A1 publication Critical patent/HK1093494A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK07100087.7A 2003-08-04 2007-01-04 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists HK1093494A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0302451A HU227534B1 (en) 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
PCT/HU2004/000056 WO2005012266A1 (en) 2003-08-04 2004-05-21 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Publications (1)

Publication Number Publication Date
HK1093494A1 true HK1093494A1 (en) 2007-03-02

Family

ID=89981557

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100087.7A HK1093494A1 (en) 2003-08-04 2007-01-04 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Country Status (37)

Country Link
US (2) US7737142B2 (hr)
EP (1) EP1663996B1 (hr)
JP (1) JP3999806B2 (hr)
KR (1) KR100870284B1 (hr)
CN (1) CN1829703B (hr)
AU (1) AU2004261490B2 (hr)
BE (1) BE2017C045I2 (hr)
BR (1) BRPI0413283B8 (hr)
CA (1) CA2532818C (hr)
CY (2) CY1113099T1 (hr)
DK (1) DK1663996T3 (hr)
EA (1) EA009022B1 (hr)
ES (1) ES2389840T3 (hr)
FR (1) FR17C0008I1 (hr)
HK (1) HK1093494A1 (hr)
HR (1) HRP20120715T1 (hr)
HU (2) HU227534B1 (hr)
IL (1) IL172746A (hr)
IS (1) IS2905B (hr)
LT (1) LTC1663996I2 (hr)
LU (1) LUC00039I2 (hr)
MA (1) MA28024A1 (hr)
ME (1) ME00564B (hr)
MX (1) MXPA06001033A (hr)
MY (1) MY142760A (hr)
NL (1) NL300913I2 (hr)
NO (2) NO334973B1 (hr)
NZ (1) NZ544999A (hr)
PL (1) PL1663996T3 (hr)
PT (1) PT1663996E (hr)
RS (1) RS52771B (hr)
SI (1) SI1663996T1 (hr)
TN (1) TNSN05328A1 (hr)
TW (1) TWI327141B (hr)
UA (1) UA84022C2 (hr)
WO (1) WO2005012266A1 (hr)
ZA (1) ZA200601026B (hr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
ES2401663T3 (es) * 2006-10-31 2013-04-23 F. Hoffmann-La Roche Ag Derivados éter moduladores duales de los receptores de 5-HT2a y D3
HUP0700269A2 (en) * 2007-04-11 2009-04-28 Richter Gedeon Nyrt Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
WO2008141135A1 (en) * 2007-05-11 2008-11-20 Forest Laboratories Holdings Limited Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
EP2185155B1 (en) * 2007-08-03 2017-10-04 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
ATE552002T1 (de) 2008-02-21 2012-04-15 Richter Gedeon Nyrt Feste zubereitung zur oralen verabreichung
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
CN102118970A (zh) * 2008-07-16 2011-07-06 吉瑞工厂 包含多巴胺受体配体的药物制剂
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
HUP0900790A2 (en) 2009-12-17 2011-09-28 Richter Gedeon Nyrt A new process for the preparation of piperazine and their hydrochloric salts
CN103130737B (zh) * 2011-12-05 2015-12-02 江苏恒谊药业有限公司 环己烷胺类化合物及其作为抗精神分裂症药物的应用
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US9598387B2 (en) 2012-10-11 2017-03-21 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
ITMI20131693A1 (it) 2013-10-14 2015-04-15 Chemo Res S L Derivati della 1,4-cicloesilammina e loro preparazione
CN105085345B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 含硝基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105085346B (zh) * 2015-08-14 2017-03-29 天津小新医药科技有限公司 含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106518841B (zh) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
CN111925304A (zh) * 2015-09-22 2020-11-13 江苏恩华药业股份有限公司 一种用于制备卡利拉嗪的化合物及其制备方法
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
CN105330616B (zh) * 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法
EP3231418A1 (en) 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CN107793350B (zh) * 2016-09-05 2021-06-04 上海医药工业研究院 芳乙基哌啶基衍生物及其治疗精神分裂症的应用
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
MX2020007849A (es) 2018-01-26 2020-09-25 Shionogi & Co Compuesto ciclico condensado que tiene efecto antagonista del receptor de dopamina d3.
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
CN108586389B (zh) * 2018-06-29 2020-06-12 成都福柯斯医药技术有限公司 一种合成卡利拉嗪的方法
CN110872262A (zh) 2018-08-29 2020-03-10 上海科胜药物研发有限公司 一种卡利拉嗪的合成方法
CN110872269B (zh) * 2018-08-30 2024-06-07 浙江京新药业股份有限公司 一种环己烷衍生物的盐
CN110872270A (zh) * 2018-08-30 2020-03-10 浙江京新药业股份有限公司 一种环己烷衍生物的盐
CN111320594A (zh) * 2018-12-13 2020-06-23 江苏恩华药业股份有限公司 一种卡利拉嗪杂质及其制备工艺和用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
CN112239433B (zh) * 2019-07-17 2024-05-14 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
CN110372557B (zh) * 2019-08-06 2021-05-18 上海勋和医药科技有限公司 环己烷胺类d3/d2受体部分激动剂
CA3157843A1 (en) 2019-10-29 2021-05-06 Shanghai Hansoh Biomedical Co., Ltd. Modifier of four-membered ring derivative, preparation method and application thereof
EP4056568A4 (en) 2019-11-05 2024-02-28 Shanghai Hansoh Biomedical Co., Ltd. BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD AND USE THEREOF
HUP2100108A1 (hu) 2021-03-12 2022-09-28 Richter Gedeon Nyrt Eljárás és berendezés gyógyászatilag alkalmazható piperazin származékok folyamatos áramú, áramlásos konszekutív redukálással történõ elõállítására
EP4332093A1 (en) 2021-04-28 2024-03-06 Shanghai Hansoh Biomedical Co., Ltd. Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
IL311268A (en) 2021-09-15 2024-05-01 Richter Gedeon Nyrt A process for the production of (1R, 4R)-4-disubstituted cyclohexane-1-amines
HUP2200312A1 (hu) 2022-08-05 2024-02-28 Richter Gedeon Nyrt Kariprazin tartalmú szájban diszpergálódó tabletta
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders
KR20240112213A (ko) 2023-01-11 2024-07-18 리히터 게데온 닐트. 도파민 d3/d2 수용체 조절 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
JP2002509918A (ja) 1998-03-31 2002-04-02 アケイディア ファーマスーティカルズ インコーポレイテッド ムスカリン性レセプタに活性を有する化合物
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
US20100240640A1 (en) 2010-09-23
BE2017C045I2 (hr) 2023-08-09
MXPA06001033A (es) 2006-04-24
KR100870284B1 (ko) 2008-11-25
HU227534B1 (en) 2011-08-29
IL172746A (en) 2016-02-29
CN1829703B (zh) 2011-06-08
NO2017051I1 (no) 2017-10-09
LUC00039I1 (hr) 2017-10-16
LTC1663996I2 (lt) 2018-05-25
US20060229297A1 (en) 2006-10-12
ES2389840T3 (es) 2012-11-02
NL300913I2 (nl) 2017-12-20
WO2005012266A1 (en) 2005-02-10
CY2017032I1 (el) 2018-02-14
IS8199A (is) 2005-12-22
IS2905B (is) 2014-10-15
BRPI0413283B1 (pt) 2021-10-05
EA009022B1 (ru) 2007-10-26
FR17C0008I1 (fr) 2018-12-07
HUP0302451A2 (hu) 2005-05-30
LUC00039I2 (hr) 2017-12-20
IL172746A0 (en) 2006-04-10
BRPI0413283A (pt) 2006-10-10
MA28024A1 (fr) 2006-07-03
DK1663996T3 (da) 2012-10-01
RS52771B (en) 2013-10-31
PT1663996E (pt) 2012-09-24
NO20061076L (no) 2006-03-06
UA84022C2 (ru) 2008-09-10
MY142760A (en) 2010-12-31
NL300913I1 (hr) 2017-11-23
KR20060058096A (ko) 2006-05-29
CA2532818C (en) 2009-07-14
ZA200601026B (en) 2007-05-30
TW200505874A (en) 2005-02-16
JP2007501215A (ja) 2007-01-25
AU2004261490A1 (en) 2005-02-10
JP3999806B2 (ja) 2007-10-31
HUS1700044I1 (hu) 2017-11-28
EP1663996B1 (en) 2012-06-20
TNSN05328A1 (en) 2007-07-10
PL1663996T3 (pl) 2012-11-30
CN1829703A (zh) 2006-09-06
NO2017051I2 (no) 2018-11-19
LTPA2017027I1 (lt) 2017-09-25
NO334973B1 (no) 2014-08-11
NZ544999A (en) 2009-07-31
HRP20120715T1 (hr) 2012-09-30
EP1663996A1 (en) 2006-06-07
RS20060041A (en) 2009-11-10
HU0302451D0 (en) 2003-10-28
ME00564A (hr) 2011-12-20
CY1113099T1 (el) 2016-04-13
EA200600364A1 (ru) 2006-06-30
SI1663996T1 (sl) 2012-10-30
AU2004261490B2 (en) 2008-08-21
BRPI0413283B8 (pt) 2021-10-05
TWI327141B (en) 2010-07-11
CA2532818A1 (en) 2005-02-10
ME00564B (me) 2011-12-20
US7737142B2 (en) 2010-06-15
CY2017032I2 (el) 2018-02-14

Similar Documents

Publication Publication Date Title
HUS1700044I1 (hu) (Tio)karbamoil-ciklohexán származékok, mint D3/D2 receptor antagonisták
AU2003241836A1 (en) Lpa receptor antagonists
IL198122A0 (en) Triazole derivatives as tachykinin receptor antagonists
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
HK1093070A1 (en) Imidazole derivatives as glutamate receptor antagonists
PL372463A1 (en) Thiazole derivatives as npy receptor antagonists
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
IL173337A0 (en) Receptor
GB0226227D0 (en) Receptors
AU2003297408A1 (en) Thiazole compounds as integrin receptor antagonists derivatives
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
AU2003286316A1 (en) 5-aminophenanthridine derivatives as npy-5 antagonists
AU2003297409A1 (en) Pyrazole compounds as integrin receptor antagonists derivatives
GB0223399D0 (en) Receptors
GB0215389D0 (en) Receptor
GB0321998D0 (en) Receptor
GB0228112D0 (en) Receptors
AU2002950373A0 (en) G protein-coupled receptor antagonists
GB0304090D0 (en) Receptors
GB0316354D0 (en) Receptors
GB0314113D0 (en) Receptors
GB0308309D0 (en) Receptors
GB0304065D0 (en) Receptors
GB0302604D0 (en) Receptors
GB0317346D0 (en) 5-ht2b receptor antagonists

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240517